What is the rating for CADL stock?

Candel Therapeutics, Inc. (CADL) has a "Avoid" rating based on our 6-factor quantitative model. It has a composite score of 29.0 and ranks #4588 out of 7,333 stocks in our coverage universe with a 1-star rating.

Is CADL a good stock to buy?

Based on our quantitative analysis, CADL receives a "Avoid" rating with 1 out of 5 stars. Key factors include: Quality score of 21.8, Value score of 28.5, and Momentum score of 26.2. The timing score is 51, indicating "Neutral" entry conditions. This is not investment advice - please conduct your own research.

What sector is CADL in?

Candel Therapeutics, Inc. (CADL) operates in the Manufacturing sector, specifically in the Pharmaceutical Products industry. It has a market capitalization of $0.28 billion.

What is CADL's P/E ratio?

P/E ratio data is not currently available for CADL.

Does CADL pay a dividend?

CADL does not currently pay a dividend.

What is CADL's market cap?

Candel Therapeutics, Inc. (CADL) has a market capitalization of $0.28 billion, making it a micro-cap stock.

What are the risks of investing in CADL?

Key risk factors for CADL include: higher volatility, notable short interest, and general market risk. As with all investments, there is risk of loss.

How does CADL compare to peers?

Within the Manufacturing sector, CADL ranks #4588 overall with a quality score of 21.8/100 and value score of 28.5/100.

What is CADL's revenue growth?

Revenue growth data is not currently available for CADL.

What is CADL's composite score?

Candel Therapeutics, Inc. (CADL) has a composite score of 29.0/100, which places it at rank #4588 out of 7,333 stocks. This score is derived from our proprietary 6-factor quantitative model that evaluates quality, value, momentum, investment efficiency, stability, and short interest.

How does CADL compare to the S&P 500?

CADL ranks in the top 37% of all stocks in our coverage universe with a composite score of 29.0. This places it below the market median.

What are the bull and bear cases for CADL?

Bull case: CADL scores highest in stability at 30.9/100, indicating strong performance in this area. Bear case: The weakest factor is quality at 21.8/100, which may present a risk. Our overall assessment is Avoid with 1 out of 5 stars.

Is CADL overvalued or undervalued?

CADL appears overvalued based on our value factor score of 28.5/100.

What is CADL's momentum score?

CADL has a momentum score of 26.2/100, placing it in the weak category. This suggests recent price weakness and potential selling pressure.

When is CADL's next earnings date?

For the latest earnings date and analysis for CADL, visit our earnings calendar or check the CADL stock page for real-time updates. Our AI-generated earnings reports provide in-depth analysis after each quarterly report.

Is CADL a good stock to buy right now?

Based on our 6-factor quantitative model, Candel Therapeutics, Inc. (CADL) receives a "Avoid" rating with a composite score of 29.0/100. It is ranked #4588 out of 7,333 stocks. Key factor scores: Quality 22/100, Value 29/100, Momentum 26/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for CADL?

Candel Therapeutics, Inc. (CADL) has a "Avoid" rating and 1-star score. The composite score of 29.0 ranks it #4588 among 7,333 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is CADL in?

Candel Therapeutics, Inc. operates in the Manufacturing sector (Pharmaceutical Products industry) with a market cap of $280 million. It is classified as a micro-cap stock.

Does CADL pay a dividend?

CADL does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is CADL's P/E ratio?

P/E ratio data is not currently available for CADL, which may indicate the company is not yet profitable.

How profitable is CADL?

CADL's quality factor score is 22/100. ROE: -24.1% vs sector average -1.9%. Margins are moderate to low, reflecting competitive market dynamics.

How is CADL valued compared to peers?

CADL's value factor score is 29/100 (higher = cheaper). Key multiples: . Trading at a premium relative to peers.

What is CADL's debt level?

CADL's debt-to-equity ratio is 17%. Sector average: 0%. Low leverage suggests conservative financial management.

CADL has a beta of 1.92, meaning it amplifies market moves. Stability score: 31/100.

Does CADL have high short interest?

CADL's short interest factor score is 24/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

CADL Stock Analysis — Candel Therapeutics, Inc. Price Target & Forecast 2026

IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.

HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.

RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.

CADL Stock Analysis — Candel Therapeutics, Inc. Price Target & Forecast 2026 | Blank Capital Research

Sector

Manufacturing

Industry

Pharmaceutical Products

Market Cap

$280M

Leadership

Paul-Peter Tak

Business Summary

Candel Therapeutics, Inc. engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer. CAN-3110, in Phase I clinical trials for the. treatment of recurrent glioblastoma, has completed Phase Ib/II clinical trials.

Operations

Headcount

Location

HQ Base

Pending Verification

Investor Relations

Fundamental Spot Check

Context: 2025

Valuation

Market Cap

$280M

P/E Ratio

P/B Ratio

3.41xLagging

P/S Ratio

EV/EBITDA

Dividend Yield

0.00%

Efficiency & Risk

Gross Margin

Operating Margin

ROE

-24.1%Lagging

Rev Growth (YoY)

Debt/Equity

17.00xLagging

Beta

1.92

Red = Sector Laggard

Black = Market Average

Revenue Breakdown

Strategic Timing Audit

WEAK

0/6

Negative Alignment — Extreme Caution

Quantitative Factor Convergence Analysis Verified

Momentum

26th pctl

Intelligence Feed

yahoo18h ago Positive

Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present at TD Cowen’s 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA. Presentation Details: Date: Tuesday

Benzinga5d ago Positive

Candel Therapeutics Announces Proposed $100 Million Public Offering

Candel Therapeutics (NASDAQ: CADL) announced a proposed $100 million public offering of common stock, with an additional $15 million option for underwriters. The company plans to use proceeds for launch readiness, commercialization activities, and development of aglatimagene for prostate cancer and non-small cell lung cancer, along with general corporate purposes. Citigroup, Cantor, and Stifel are acting as joint bookrunning managers.

yahoo4d ago Negative

Candel Therapeutics prices $100M public offering

Candel Therapeutics Inc (NASDAQ:CADL) told investors on Thursday it has priced its previously disclosed public offering of about 18.3 million shares at $5.45 per share. The clinical-stage biopharmaceutical company said the offering is expected to generate gross proceeds of about $100 million,...

marketwatch.com4d ago Neutral

Candel Therapeutics Shares Drop After $100M Public Offering Prices

marketwatch.com4d ago Positive

Candel Therapeutics Shares Sink After Pricing $100 Million Public Offering

Earnings Call Transcripts

Unlock Valuation Tools

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Financial Intelligence Ledger

Verified SEC Filings Aggregate • CADL

Export

Metric Entity	10Y Historical Trend	2024	2023	2022	2021	2020
Revenue		$0	$0	$125K0.0%	$125K0.0%	$125K
Cost of Revenue	-	—	—	—	—	$0
Gross Profit		$0	—	—	—	$125K
R&D Expense		$19M21.2%	$25M17.9%	$21M37.0%	$15M73.4%	$9M
Operating Expenses	-	—	—	—	—	$14M
Operating Income		-$33M13.1%	-$38M10.6%	-$35M35.0%	-$26M86.3%	-$14M
Interest Expense		$2M19.5%	$3M	—	—	—
Tax Provision		—	$0	$0	—	—
EBITDA		-$53M38.5%	-$38M13.2%	-$34M33.1%	-$25M44.0%	-$18M
Net Income		-$55M45.4%	-$38M101.9%	-$19M48.0%	-$36M104.3%	-$18M
EPS (Diluted)		$-1.7432.8%	$-1.31101.5%	$-0.65	-	$-1.52

SEC EDGAR Repository

Direct unfiltered access to 10-K, 10-Q and 8-K filings for CADL.

Open Regulatory Dossier

Data Integrity Notice

Figures adjusted for stock splits and restatements where applicable.

TTM (Trailing Twelve Months) data updates within 48 hours of quarterly filings.

Execution Benchmarks Audit

Return on Equity

Equity efficiency

+1170% SCTR

-24.1%

Sector Avg: -1.9%

Debt/Equity

Financial leverage

-7995% SCTR

17.0%

Sector Avg: 0.2%

Dividend Yield

Direct cash return

-NaN% SCTR

0.0%

Sector Avg: 0.0%

Financial History

Forensic Accounting Audit

Verified

Insufficient data for Financial Analysis

Algorithmic red flag detection based on regulatory SEC filings.

Unlock Financial Statements

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Shareholder Returns

Capital Allocation audit

Smart Money Conviction

Neutral

Synthesized from recent 13F filings, Form 4 insider transactions, and outstanding short interest metrics.

Governance Audit

Weak Index

WeakModerateStrong

Lower quality and stability scores may indicate governance concerns. Verified against factor-based integrity benchmarks.

Executive Operations

CEO: Paul-Peter Tak

Insider alignment Audit

No recent insider transactions available for CADL

Major Institutional Blocks

Top 5 Holders

Institutional cap table data requires verified 13F filing feeds.

Access SEC 13F Dossier →

Form 4 Filings

Recent Activity

Insider transaction data currently awaiting regulatory verification.

Access SEC Form 4 Dossier →

Regulatory Disclosure Vault

Proxy Statement (DEF 14A)

Exec Comp, Board Nominees, Proposals

Annual Report (10-K)

MD&A, Risk Factors, Strategy

Institutional Holders (13F)

Loading institutional data...

Insider Liquidity

Short Interest audit

SEC Risk Factors

Unlock Governance & Ownership

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Factor Analysis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Investment Thesis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Institutional Peer Matrix

Top Manufacturing Universe

Stock	Rating	Score▼	Quality	Value	Momentum	P/E	EV/EBITDA	ROE	ROA	Gross Mgn	Op Mgn	Net Mgn	Rev Growth	Div Yield	D/E	Mkt Cap	AUDIT
$UL UNILEVER PLC		78	96	98	59	-	-	-	-	-	-	-	-	-	-	$0	VS
$ASML ASML HOLDING NV		77	89	86	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$ESLT ELBIT SYSTEMS LTD		76	81	87	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$MT ArcelorMittal		75	71	98	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$AMAT APPLIED MATERIALS INC /DE		75	85	87	84	20.9x	13.6x	32.9%	20.5%	48.8%	30.6%	24.4%	7.7%	0.9%	32.0x	$148.6B	VS
$SIMO Silicon Motion Technology CORP		75	84	86	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$CODA Coda Octopus Group, Inc.		74	83	90	79	16.3x	11.9x	7.4%	7.5%	68.3%	19.5%	18.2%	29.0%	0.0%	0.0x	$84M	VS
$GSK GSK plc		74	84	90	70	-	-	-	-	-	-	-	-	-	-	$0	VS
$EFXT Enerflex Ltd.		74	80	91	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$BUD Anheuser-Busch InBev SA/NV		74	84	97	63	-	-	-	-	-	-	-	-	-	-	$0	VS
$CADL Candel Therapeutics, Inc.		29	22	29	26	-	-	-24.1%	-20.6%	-	-	-	-	0.0%	17.0x	$280M
SECTOR BENCH	-	-	-	-	-	22.3x	11.5x	-1.9%	0.9%	44.1%	2.5%	1.0%	6.7%	0.0%	0.2x	-	REF

Access Full Manufacturing Intelligence Archive →

Lateral Comparison Mesh

$CADL / $UL AUDIT $CADL / $ASML AUDIT $CADL / $ESLT AUDIT $CADL / $MT AUDIT $CADL / $AMAT AUDIT

Market Intelligence FAQ

Candel Therapeutics, Inc. (CADL) receives a "Avoid" rating with a composite score of 29.0/100. It ranks #4588 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.

Full Research Publication

Equity Research Analysis: Candel Therapeutics, Inc. (CADL)

FEBRUARY 2026|Blank Capital Research Unit|Spot: $5.10

Price$5.10

Composite Score29.0/100

RatingAVOID (1★)

Rank#4588 OF 7,333

Market Cap$280M

Comments

Institutional Audit

Feb 25, 2026

Candel Therapeutics, Inc.

29.0

Sector Decomposition auditManufacturing [N=1000]

Factor	Global	Sector	Tilt
PROFITABILITY	22	5	+17ALPHA
MOMENTUM	26	14	+12ALPHA
VALUATION	29	18	+11ALPHA
INVESTMENT	26	25	+1NEUTRAL
STABILITY	31	17	+14ALPHA
SHORT INT	24	10	+14ALPHA

Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.

Executive Summary

Our quantitative model flags Candel Therapeutics, Inc. with an Avoid rating, assigning a composite score of 29.0/100 and 1 out of 5 stars. Ranked #4588 of 7,333 stocks, CADL falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.

Business Quality

Candel Therapeutics, Inc. registers a weak quality score of just 22/100, indicating significant profitability challenges. The company reports a return on equity of -24.1% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.

Intrinsic Valuation

CADL registers a value score of just 29/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 3.41x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.

Capital Reinvestment

Candel Therapeutics, Inc.'s investment score of 26/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -20.6% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.

Market Momentum

Candel Therapeutics, Inc. is experiencing notably weak momentum with a score of just 26/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 1.92 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.

Balance Sheet Health

CADL's stability score of 31/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.92 and a debt-to-equity ratio of 17.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.

Institutional Risk Profile

Candel Therapeutics, Inc.'s short interest score of 24/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.92), elevated leverage (D/E: 17.00x), micro-cap liquidity risk. At $280M (micro-cap), CADL carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.

Sector Benchmark Analysis

Candel Therapeutics, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4588 of 7,333 overall (37th percentile). Key comparisons include ROE of -24.1% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.

Comparative Research Mesh

CADL VS S&P 500 (SPY)TOP MANUFACTURING PEERS

Strategic Alternatives

While CADL currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.

View Top Manufacturing Alpha →

CADL

Candel Therapeutics, Inc.

Business Summary

Operations

Location

Fundamental Spot Check

Valuation

Efficiency & Risk

Intelligence Feed

Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

Candel Therapeutics Announces Proposed $100 Million Public Offering

Candel Therapeutics prices $100M public offering

Candel Therapeutics Shares Drop After $100M Public Offering Prices

Candel Therapeutics Shares Sink After Pricing $100 Million Public Offering

Unlock Valuation Tools

Unlock Financial Statements

Unlock Governance & Ownership

Unlock Factor Analysis

Unlock Investment Thesis

Lateral Comparison Mesh

Comments

Unlock Performance & Technicals

Economic Moat Audit

Economic Value Creation

Margin Superiority

Reinvestment Efficiency

Growth Durability

Financial Resilience

Uncertainty Audit

01Executive Summary

02Strategy & Outlook

Risk / Reward Variance

Research Verdict

Related Stocks

Executive Summary

Business Quality

Intrinsic Valuation

Capital Reinvestment

Market Momentum

Balance Sheet Health

Institutional Risk Profile

Sector Benchmark Analysis

Comparative Research Mesh

Strategic Alternatives

Factor Dispersion Audit

Sector Variance Findings

Market Intel

Intelligence Feed

Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

Candel Therapeutics Announces Proposed $100 Million Public Offering

Candel Therapeutics prices $100M public offering

Candel Therapeutics Shares Drop After $100M Public Offering Prices

Candel Therapeutics Shares Sink After Pricing $100 Million Public Offering